Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in NTLA.
← Back to Free Index

NTLA

Analysis as of: 2026-04-28
Intellia Therapeutics, Inc.
Intellia develops in vivo CRISPR-based gene-editing therapies for hereditary angioedema, ATTR amyloidosis, and other severe diseases.
ai biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Gene editing nears commercial proof
Positive HAE Phase 3 data and a rolling filing move the story from scientific promise to launch execution. The upside now depends on converting one approved rare-disease franchise into a broader in vivo editing business without repeating ATTR safety friction.

Analysis

Thesis
Positive HAE Phase 3 data and a rolling BLA give Intellia a credible path to become the first broadly commercial in vivo CRISPR rare-disease franchise; if lonvo-z launches in 2027 and ATTR regains momentum, HAE cash flow plus platform deals can compound meaningfully by 2031.
Last Economy Alignment
Moderately positive: AI can accelerate discovery and operations, but value capture rests on regulated IP, clinical data, and trust, with biology and approval still the binding gates.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.5x (from 5 most recent analyses)
Reasoning
I underwrite Intellia as a rare-disease launch story with platform spillover, not a full blue-sky editing winner. A successful lonvo-z launch can shift the company from cash-burning science asset to commercial biotech, while nex-z and selective partner deals add upside. The multiple stays below top rare-disease leaders because approval history, first-launch execution, and one-time-therapy adoption still cap confidence.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
Risk has shifted from pure HAE clinical proof toward approval, launch, and financing discipline. Lonvo-z now looks materially more real, but Intellia is still a milestone-fragile company: value remains concentrated in a few regulatory events, early commercial execution for a one-time therapy, and whether nex-z can rebuild trust without renewed safety setbacks.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.27
They own gene-editing IP, clinical data, and regulatory know-how that AI cannot easily copy, so the product is not likely to get software-like price compression. AI can help the science and operations, but the business still rises or falls on approvals, safety, and earning trust for one-shot treatments.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$20.45
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case